SCHEMBL11216725

SCHEMBL11216725

COC(=O)CCc1ccc(O)c(N)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.71
GAA P10253 2/20 0.71
GFER P55789 1/20 0.71
ALOX5 P09917 1/20 0.51
OR51E2 Q9H255 1/20 0.51
APP P05067 2/20 0.50
MET P08581 1/20 0.46
IAPP P10997 3/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
PTPN1 P18031 2/20 0.43
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21907056 0.89 ALDH1A1 (0.66) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL23582361 0.87 GAA (0.54) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL18046156 0.87 ALDH1A1 (0.53) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL3274537 0.85 APP (0.68) ALDH1A1GFERALOX5OR51E2APP
SCHEMBL7158157 0.84 CYP4F2 (0.58) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL287469 0.83 GAA (1.00) ALDH1A1GAAGFERMETTSHR
Hydrochloric Acid SCHEMBL9713994 0.83 CYP4F2 (0.56) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL1905900 0.83 ALDH1A1 (0.49) ALDH1A1GAAGFERSIRT2PTPN1
SCHEMBL22187923 0.83 ALDH1A1 (0.49) ALDH1A1GAAGFERALOX5OR51E2
SCHEMBL3949236 0.83 GAA (0.57) ALDH1A1GAAGFERALOX5OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
EP-4071147-B1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEMICAL LTD (KR) 2025-03-26 EP disclosed
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-16 US disclosed
EP-4071147-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF Lg Chem, Ltd. (KR) 2022-10-12 EP disclosed
CN-114846013-A Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2022-08-02 CN disclosed
WO-2021133035-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF 주식회사 엘지화학 2021-07-01 WO disclosed
WO-2011150079-A1 TARGETED PROBES OF CELLULAR PHYSIOLOGY CARNEGIE MELLON UNIVERSITY (US) 2011-12-01 WO disclosed
EP-0081321-A1 2-Aminophenol derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1983-06-15 EP disclosed
US-3985763-A DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF DGAT2, DGAT1, PLAAT2 ALDH1A1 480/4885GAA 343/4885GFER 1159/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 ALDH1A1 597/4885GAA 791/4885GFER 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.